Status:
COMPLETED
Association of Breg and Treg With the Clinical Effects of Infliximab in the Treatment of Patients With Crohn's Disease
Lead Sponsor:
Second Affiliated Hospital of Wenzhou Medical University
Conditions:
Crohn Disease
Eligibility:
All Genders
18+ years
Brief Summary
Aims: The main aim of this study is to access the predictive value of Treg and Breg for the clinical effect of Infliximab in the treatment through analyzing the relationship between Breg and Treg and ...
Detailed Description
1. Patients with CD at initial active stage are collected from department of gastroenterology, the Second Affiliated Hospital of Wenzhou Medical University. The diagnosis of CD is based on clinical, e...
Eligibility Criteria
Inclusion
- CD patients
- Crohn's Disease at initial active stage with CDAI ≥150.
- Starting Infliximab treatment
Exclusion
- Significant co-morbidity (e.g. cancer, intestinal tuberculosis, ischemic enteritis, radiation enteritis)
- Other immunological disease (e.g. diabetes, rheumatoid arthritis systemic lupus erythematosus)
- Current treatment with glucocorticoids, immunosuppressants and biological agents
- Healthy controls
- Inclusion Criteria:
- No current disease
- No daily drug use
Key Trial Info
Start Date :
January 24 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 29 2019
Estimated Enrollment :
32 Patients enrolled
Trial Details
Trial ID
NCT04272788
Start Date
January 24 2017
End Date
September 29 2019
Last Update
February 17 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
SAHWenzhouMU
Wenzhou, Zhejiang, China